Abstract
The treatment landscape for gastroesophageal adenocar-cinomas has significantly changed over the last year. The addition of nivolumab to first-line chemotherapy has led to survival benefit in patients who have metastatic gastroesophageal adenocarcino-ma with a programmed death ligand 1 combined positive score of 5 or greater. Similarly, in patients with metastatic human epidermal growth factor receptor 2 (HER2)–positive gastroesophageal adenocarcinoma, the addition of pembrolizumab to chemotherapy and trastuzumab has significantly improved efficacy. Furthermore, a phase 2 study revealed that trastuzumab deruxtecan, a new anti-body-drug conjugate, significantly improved survival in comparison with chemotherapy among patients with HER2-positive gastric cancer in the refractory setting, and it produced a signal of efficacy in the second-line setting. Chemoimmunotherapy combinations are now considered the standard of care for a significant number of patients with gastroesophageal adenocarcinomas.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 169-177 |
| Number of pages | 9 |
| Journal | Clinical Advances in Hematology and Oncology |
| Volume | 20 |
| Issue number | 3 |
| State | Published - Mar 2022 |
Keywords
- Esophageal cancer
- Gastric cancer
- Gastroesophageal adenocarcinoma
- Nivolumab
- Pembrolizumab
- Trastuzumab deruxtecan
ASJC Scopus subject areas
- Hematology
- Oncology